TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06310369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents.
Study: NCT06043063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Description: Topical anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Topical lidocaine
Description: Topical anesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: Topical anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Topical anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periurethral block
Description: 5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
Study: NCT06379750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-delivered care using WelTel check-ins and BCC SMS
Description: Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-delivered care using WelTel check-ins and BCC SMS
Description: Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based peer-support model
Description: Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based peer-support model
Description: Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring
Study: NCT04648969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: 20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 1 intravenous dose of GnRH
Study: NCT04561999

Intervention type: DEVICE
Intervention: Elastography
Description: Performance of Ultrasound, Elastography
Study: NCT05167552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olfactory mucosa-derived mesenchymal stem cells
Description: Olfactory mucosa-derived mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olfactory mucosa-derived mesenchymal stem cells
Description: Olfactory mucosa-derived mesenchymal stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of type Allergic Rhinitis according to the clinical protocols
Description: Standard treatment of type Allergic Rhinitis according to the clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment of type Allergic Rhinitis according to the clinical protocols
Description: Standard treatment of type Allergic Rhinitis according to the clinical protocols

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
Description: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
Description: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
Study: NCT06131671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles.
Study: NCT04759183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Participate in VR Game Angry Birds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Participate in VR Game Angry Birds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Meditation
Description: Participate in VR Meditation TRIPP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Meditation
Description: Participate in VR Meditation TRIPP
Study: NCT04711837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 for induction of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for induction of general anesthesia.
Study: NCT05257122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg qd, d1-21, q28d
Study: NCT05319964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill
Description: Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treadmill
Description: Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
Study: NCT05239104

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention
Study: NCT05533801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab will be administered subcutaneously using a vial and syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab will be administered subcutaneously using AI.
Study: NCT06275217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based yoga program
Description: The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
Study: NCT05200637

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro stent
Description: Orsiro stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience stent
Description: Xience stent

Intervention type: DEVICE
Group type: OTHER
Intervention: Any drug-eluting stent
Description: Any drug-eluting stent
Study: NCT06374797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxora
Description: 1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
Study: NCT05272644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyographic biofeedback assisted pelvic floor muscle training
Description: participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
Study: NCT05752643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online follow up
Description: The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
Study: NCT05818189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized tactile cueing
Description: We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed tactile cueing
Description: We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
Study: NCT06226077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep extension intervention
Description: The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
Study: NCT05272644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyographic biofeedback assisted pelvic floor muscle training
Description: participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surface electromyographic biofeedback and electrical stimulation
Description: participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surface electromyographic biofeedback and electrical stimulation
Description: participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
Study: NCT05930366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival depigmentation using microsurgery
Description: GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival Depigmentation using Diode Laser
Description: GINGIVAL DEPIGMENTAION USING DIODE LASER
Study: NCT05880823

Intervention type: DEVICE
Intervention: Synergy cervical disc system
Description: motion preservation disc

Intervention type: DEVICE
Intervention: Synergy cervical disc system
Description: motion preservation disc
Study: NCT05860374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05399576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Prophylactically combined intracoronary of Nicorandil and verapamil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intracoronary of 4ml saline
Study: NCT06226077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: contact control intervention
Description: The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
Study: NCT04920149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: The IMP will be supplied as sachets with slow-releasing granules.
Study: NCT05658523

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Moderna
Description: A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novavax
Description: A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
Study: NCT05793229

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT05117957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
Study: NCT05329571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Description: Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free Diet
Description: Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
Study: NCT04920149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The IMP will be supplied as sachets with slow-releasing granules.
Study: NCT05089071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist by artificial intelligence system for colon polyp detection
Description: Assist by artificial intelligence system for colon polyp detection
Study: NCT05242315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus Oral Product
Description: as described in arm/group description

Intervention type: DRUG
Group type: OTHER
Intervention: Prograf (SOC)
Description: Prograf (SOC)
Study: NCT05025748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete questionnaires
Study: NCT06560437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese Jingjin Manual Therapy
Description: Chinese Jingjin therapy is a form of manual therapy that utilizes the principles of Chinese Jingjin Theory (also known as Chinese Sinew Channel Theory) to alleviate nodular lesions in sinew channels caused by Jingjin injuries and to realign skeletal joints. Chinese Jingjin manual therapy is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
Study: NCT05985772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Operative Pain Management
Description: The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment
Description: The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
Study: NCT05574647

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: bpMRI
Description: biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Image-Fusion targeted and systematic Biopsy
Description: During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
Study: NCT06430827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride liposome injection
Description: rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
Study: NCT06120972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
Study: NCT06430060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc containing toothpaste
Description: Toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MFP Fluoride toothpaste
Description: toothpaste
Study: NCT04247971

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 23 ml of blood collected

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 23 ml of blood collected

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 23 ml of blood collected

Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Induced sputum sample collected

Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Induced sputum sample collected

Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Induced sputum sample collected

Intervention type: PROCEDURE
Intervention: Pulmonary function test
Description: Pulmonary function testing

Intervention type: PROCEDURE
Intervention: Pulmonary function test
Description: Pulmonary function testing

Intervention type: PROCEDURE
Intervention: Pulmonary function test
Description: Pulmonary function testing
Study: NCT05118269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment plus Optimal Medical Therapy
Description: Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study: NCT05313152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO103A
Description: TAVO103A single ascending dose IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO103A
Description: TAVO103A single ascending dose IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO103A
Description: TAVO103A single ascending dose IV infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single ascending dose IV infusion.
Study: NCT05353803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
Description: Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
Study: NCT04416581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-CAB 50
Description: tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.